Arcus Biosciences (Arcus Biosciences) Cash-to-Debt : 69.00 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Arcus Biosciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Arcus Biosciences's cash to debt ratio for the quarter that ended in Dec. 2023 was 69.00.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Arcus Biosciences could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Arcus Biosciences's Cash-to-Debt or its related term are showing as below:

RCUS' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.27 Med: 5168.17 Max: No Debt
Current: 69

During the past 8 years, Arcus Biosciences's highest Cash to Debt Ratio was No Debt. The lowest was 4.27. And the median was 5168.17.

RCUS's Cash-to-Debt is ranked better than
76.22% of 1539 companies
in the Biotechnology industry
Industry Median: 6.46 vs RCUS: 69.00

Arcus Biosciences Cash-to-Debt Historical Data

The historical data trend for Arcus Biosciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Arcus Biosciences Cash-to-Debt Chart

Arcus Biosciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

47.80

4.27

336.33

69.00

Arcus Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															336.33	No Debt	No Debt	88.78	69.00

Competitive Comparison of Arcus Biosciences's Cash-to-Debt

For the Biotechnology subindustry, Arcus Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arcus Biosciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcus Biosciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Arcus Biosciences's Cash-to-Debt falls into.

Arcus Biosciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Arcus Biosciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	759	/	(11	+	0)
	=	69.00

Arcus Biosciences's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	759	/	(11	+	0)
	=	69.00

Arcus Biosciences (NYSE:RCUS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Arcus Biosciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Arcus Biosciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Arcus Biosciences (Arcus Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcus Biosciences Inc (NYSE:RCUS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

3928 Point Eden Way, Hayward, CA, USA, 94545

Website

https://www.arcusbio.com

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies.

Executives

Goeltz Ii Robert C.	officer: Chief Financial Officer	343 OYSTER POINT BLVD, SUITE 100, SOUTH SAN FRANCISCO CA 94080
Juan C. Jaen	director, 10 percent owner, officer: President	850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043
Jennifer Jarrett	officer: See Remarks	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Alexander Azoy	officer: Chief Accounting Officer	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Gilead Sciences Inc	10 percent owner	333 LAKESIDE DR, FOSTER CITY CA 94404
Terry J Rosen	director, 10 percent owner, officer: Chief Executive Officer	C/O TULARK INC, TWO CORP DRIVE S, SAN FRANCISCO CA 94080
Carolyn C. Tang	officer: General Counsel	3928 POINT EDEN WAY, HAYWARD CA 94545
Dimitry Sa Nuyten	officer: Chief Medical Officer	740 HEINZ AVENUE, C/O ADURO BIOTECH, INC., BERKELEY CA 94710
Linda Slanec Higgins	director	3610 LOUIS RD., PALO ALTO CA 94303
Nicole Lambert	director	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
William Grossman	officer: Chief Medical Officer	C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Yasunori Kaneko	director, 10 percent owner	509 ROEHAMPTON, HILLS BOROUGH CA 94010
Kathryn E Falberg	director	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Michael Quigley	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Andrew J Perlman	director	618 MIRADA AVE, STANFORD CA 94305